Pentavalent Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Pentavalent Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Pentavalent Market:

https://www.thebusinessresearchcompany.com/report/pentavalent-global-market-report

According to The Business Research Company’s Pentavalent Global Market Report 2024, The pentavalent market size has grown steadily in recent years. It will grow from $2.53 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to global immunization initiatives, government vaccination programs, prevention of multiple diseases, public health awareness, international partnerships and funding.

The pentavalent market size is expected to see steady growth in the next few years. It will grow to $3.17 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to continued global immunization efforts, expansion of vaccination programs, introduction in new geographies, research and development initiatives, collaborations for vaccine access. Major trends in the forecast period include global health initiatives and funding support, public awareness and education campaigns, government policies and regulatory frameworks, technological innovations in vaccine manufacturing.

The rising prevalence of diphtheria is expected to boost the growth of the pentavalent market going forward. Corynebacterium diphtheriae is a bacterium that causes the severe, extremely contagious disease known as diphtheria. Diphtheria causes severe difficulties with eating and breathing, as well as the possibility of skin ulcers. The pentavalent vaccine protects children from Diphtheria diseases by a pentavalent immunization in a 3-dose schedule, as a result, the rising prevalence of diphtheria increased the demand for pentavalent vaccines. For instance, in 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, an unusually high number of reported cases of diphtheria were recorded through the International Health Regulations (IHR) reporting process, primarily in the months of June and August 2022. Seven nations have documented 144 instances of diphtheria, many of which were among asylum seekers. Among 144 patients, 97 (69%) were determined to be clinically compatible, 44 (31%) to be toxigenic diphtheria cases by laboratory confirmation, and 3 (2%) were suspected cases. Therefore, the rising prevalence of diphtheria is driving the growth of the pentavalent market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9104&type=smp

The pentavalent market covered in this report is segmented –

1) By Type: Sodium Stibogluconate, Meglumine Antimoniate

2) By Formulation Type: Lyophilized, Liquid

3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

Major companies operating in the pentavalent market are focused on developing innovative solutions such as pentavalent immunization vaccines. Pentavalent immunization vaccines are a type of combination vaccine designed to protect against five different diseases. For instance, in October 2023, Pfizer, a US-based pharmaceutical company announced the FDA approval for its ‘Penbraya’ pentavalent vaccine. It is the initial and sole pentavalent vaccine providing protection against the five most prevalent meningococcal serogroups—A, B, C, W-135, and Y—in individuals aged 10 through 25 years. The vaccine merges elements from the Trumenba meningococcal group B vaccine and the Nimenrix meningococcal groups A, C, W-135, and Y conjugate vaccine. Penbraya has been identified as effective in providing protection against the five meningococcal serogroups responsible for the majority of global cases of invasive meningococcal disease.

The pentavalent market report table of contents includes: